Abstract： Objective： To observe the clinical effect of Bailing capsules combined with valsartan for chronic glomerulonephritis(CGN). Methods：A total of 90 cases of CGN patients were selected and divided into the observation group and the control group according to random number table method，with 45 cases in each group. The control group was treated with valsartan dispersible tablets， and the observation group was additionally treated with Bailing capsules based on the treatment of the control group. Both groups were treated for eight weeks continuously. The indexes of kidney function and the levels of interleukin-17(IL-17) ， soluble fms-like tyrosine kinase-1(sFlt-1) and tissue-type plasminogen activator (t- PA) before and after treatment and the clinical effects in the two groups were compared. The adverse reactions were recorded. Results：The total effective rate was 91.1% in the observation group，higher than that of 75.6% in the control group (P＜0.05). After treatment，the estimated glomerular filtration rates(eGFR) in the two groups were increased when compared with those before treatment(P＜0.05)， and the levels of 24- hour urine protein， blood urea nitrogen(BUN) and serum creatinine(SCr) were decreased(P＜0.05)；eGFR in the observation group was higher than that in the control group(P＜0.05)， and the levels of 24-hour urine protein，BUN and SCr were lower(P＜0.05). After treatment，the levels of IL-17 and sFIt-1 in serum in the two groups were decreased when compared with those before treatment(P＜0.05)，and the t- PA levels in serum were increased(P＜0.05)；the levels of IL-17 and sFIt-1 in serum in the observation group were lower than those in the control group(P＜0.05)，and t-PA level in serum was higher(P＜0.05). During treatment，there was no serious adverse reaction in the two groups. Conclusion：Bailing capsules combined with valsartan has a good curative effect in treating CGN， which can effectively improve kidney function with high safety.